130 related articles for article (PubMed ID: 26732524)
1. Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.
Tam CS; Polliack A
Leuk Lymphoma; 2016; 57(6):1247-8. PubMed ID: 26732524
[No Abstract] [Full Text] [Related]
2. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Strati P; Ferrajoli A; Wierda WG; Jain N; Thompson PA; O'Brien SM; Rezvani K; Kantarjian HM; Burger JA; Hinojosa CO; Keating MJ; Estrov Z
Leukemia; 2018 Oct; 32(10):2278-2281. PubMed ID: 29479067
[No Abstract] [Full Text] [Related]
3. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Brown JR
Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
[TBL] [Abstract][Full Text] [Related]
4. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
5. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Moutouh-de Parseval LA; Weiss L; DeLap RJ; Knight RD; Zeldis JB
J Clin Oncol; 2007 Nov; 25(31):5047. PubMed ID: 17971612
[No Abstract] [Full Text] [Related]
6. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
Chanan-Khan A; Egyed M; Robak T; Martinelli de Oliveira FA; Echeveste MA; Dolan S; Desjardins P; Blonski JZ; Mei J; Golany N; Zhang J; Gribben JG
Leukemia; 2017 May; 31(5):1240-1243. PubMed ID: 28140392
[No Abstract] [Full Text] [Related]
7. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
8. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
9. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Awais A; Tam CS; Kontoyiannis D; Ferrajoli A; Duvic M; Cortes J; Keating MJ
Clin Infect Dis; 2008 Apr; 46(7):e69-71. PubMed ID: 18444808
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
12. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
13. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
Byrd JC; Lin TS; Grever MR
Semin Oncol; 2006 Apr; 33(2):210-9. PubMed ID: 16616068
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Miller KC; Musial L; Whitworth A; Chanan-Khan A
Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
[TBL] [Abstract][Full Text] [Related]
18. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Pinto A; Corazzelli G; De Filippi R
Cancer; 2012 Mar; 118(6):1738; author reply 1739. PubMed ID: 21766303
[No Abstract] [Full Text] [Related]
19. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia.
Kriachok IA
Exp Oncol; 2012 Dec; 34(4):378-80. PubMed ID: 23303003
[No Abstract] [Full Text] [Related]
[Next] [New Search]